PTPRZ1 and central nervous system cancer: Historically, a first in vivo attempt to therapeutically exploit PTPRZ overexpression in glioma dates back to 2006 when a saporin-coupled antibody against the PTPRZ-B extracellular domain was found to significantly delay human U87 glioma tumor growth in a subcutaneous mouse xenograft model [126].